Skip to main content
See every side of every news story
Published loading...Updated

Novo Nordisk Executive Reports High Interest for Once-Daily, Oral Weight-Loss Pill

Novo Nordisk's oral Wegovy pill offers a lower-cost, needle-free option with 14%-17% average weight loss but faces adherence challenges, with only 27% maintaining use at one year.

Summary by Fox Business
Wegovy’s oral version of its injectable weight-loss drug is seeing tremendous interest, Novo Nordisk executive Dave Moore told FOX Business on Friday.Wegovy’s once-daily pill, an oral spinoff of its injectable weight-loss medication, was approved in December 2025 by the Food and Drug Administration as the first oral GLP-1 drug and launched on U.S. markets Monday. "There are so many patients that have been on the sidelines just waiting because th…

6 Articles

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 50% of the sources lean Left, 50% of the sources lean Right
50% Right

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

Verywell Health broke the news in on Saturday, January 10, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

News
Feed Dots Icon
For You
Search Icon
Search
Blindspot LogoBlindspotLocal